CA2526663C - Derives indoliques possedant une activite d'induction de l'apoptose - Google Patents

Derives indoliques possedant une activite d'induction de l'apoptose Download PDF

Info

Publication number
CA2526663C
CA2526663C CA2526663A CA2526663A CA2526663C CA 2526663 C CA2526663 C CA 2526663C CA 2526663 A CA2526663 A CA 2526663A CA 2526663 A CA2526663 A CA 2526663A CA 2526663 C CA2526663 C CA 2526663C
Authority
CA
Canada
Prior art keywords
tautomer
stereoisomer
indole derivative
substituted
physiologically tolerated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2526663A
Other languages
English (en)
Other versions
CA2526663A1 (fr
Inventor
Matthias Gerlach
Tilmann Schuster
Peter Emig
Peter Schmidt
Silke Bassner
Eckhard Guenther
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03012868A external-priority patent/EP1484329A1/fr
Priority claimed from EP04011598A external-priority patent/EP1595878A1/fr
Application filed by Zentaris AG filed Critical Zentaris AG
Publication of CA2526663A1 publication Critical patent/CA2526663A1/fr
Application granted granted Critical
Publication of CA2526663C publication Critical patent/CA2526663C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2526663A 2003-06-05 2004-05-25 Derives indoliques possedant une activite d'induction de l'apoptose Expired - Fee Related CA2526663C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US47627703P 2003-06-05 2003-06-05
US60/476,277 2003-06-05
EP03012868.0 2003-06-06
EP03012868A EP1484329A1 (fr) 2003-06-06 2003-06-06 Dérivés d'indole déstinés à l'induction d'apoptose
EP04011598.2 2004-05-15
EP04011598A EP1595878A1 (fr) 2004-05-15 2004-05-15 Derives d'indole destines a l'induction d'apoptose
PCT/EP2004/005593 WO2004108702A1 (fr) 2003-06-05 2004-05-25 Derives indoliques possedant une activite d'induction de l'apoptose

Publications (2)

Publication Number Publication Date
CA2526663A1 CA2526663A1 (fr) 2004-12-16
CA2526663C true CA2526663C (fr) 2011-07-19

Family

ID=43661564

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2526663A Expired - Fee Related CA2526663C (fr) 2003-06-05 2004-05-25 Derives indoliques possedant une activite d'induction de l'apoptose

Country Status (12)

Country Link
EP (1) EP1641777A1 (fr)
JP (1) JP4878285B2 (fr)
KR (1) KR101132599B1 (fr)
CN (1) CN1816543B (fr)
AU (1) AU2004245198B2 (fr)
BR (1) BRPI0410998A (fr)
CA (1) CA2526663C (fr)
MX (1) MXPA05013121A (fr)
NZ (1) NZ543853A (fr)
RS (1) RS20050901A (fr)
RU (1) RU2327696C2 (fr)
WO (1) WO2004108702A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
EP1790342A1 (fr) 2005-11-11 2007-05-30 Zentaris GmbH Dérivés de pyridopyrazine et leur utilisation comme modulateurs de transduction de signal
JP5527972B2 (ja) * 2005-11-11 2014-06-25 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のピリドピラジン及び前記ピリドピラジンをキナーゼのモジュレーターとして用いる使用
EP1956910B1 (fr) * 2005-11-23 2014-09-17 The Board of Regents of The University of Texas System Compose cytotoxique speficique du ras oncogene et ses procedes d'utilisation
EP2049520A4 (fr) * 2006-08-07 2011-01-05 Ironwood Pharmaceuticals Inc Composés d'indole
WO2008066807A1 (fr) * 2006-11-28 2008-06-05 Ziopharm Oncology, Inc. Utilisation de dérivés d'acide indolyl-3-glyoxylique comprenant de l'indibuline, seuls ou combinés à d'autres agents, pour traiter le cancer
ES2565778T3 (es) * 2008-10-16 2016-04-06 Array Biopharma, Inc. Inhibidores de mitosis para incrementar la apoptosis en terapia
WO2012017325A2 (fr) * 2010-07-19 2012-02-09 Procaps Sa Dispositif et procédé pour encapsuler des microparticules avec du liquide dans des capsules molles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
TWI269654B (en) * 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
IT1318641B1 (it) * 2000-07-25 2003-08-27 Novuspharma Spa Ammidi di acidi 2-(1h-indol-3-il)-2-oxo-acetici ad attivita'antitumorale.
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
WO2003022280A2 (fr) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 3-glyoxlylamide-indoles pour traitement du cancer

Also Published As

Publication number Publication date
CN1816543B (zh) 2011-01-19
KR20060034230A (ko) 2006-04-21
CN1816543A (zh) 2006-08-09
BRPI0410998A (pt) 2006-07-04
JP2007523850A (ja) 2007-08-23
RU2006100022A (ru) 2006-05-27
KR101132599B1 (ko) 2012-06-21
EP1641777A1 (fr) 2006-04-05
WO2004108702A1 (fr) 2004-12-16
JP4878285B2 (ja) 2012-02-15
MXPA05013121A (es) 2006-03-17
RU2327696C2 (ru) 2008-06-27
RS20050901A (en) 2007-12-31
AU2004245198A1 (en) 2004-12-16
NZ543853A (en) 2009-09-25
CA2526663A1 (fr) 2004-12-16
AU2004245198B2 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
CN110036007B (zh) 吡啶化合物
JP5828201B2 (ja) ナフタレン誘導体
JP2024012540A (ja) Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
WO2001007411A1 (fr) Derives de biaryluree
KR20050058338A (ko) ＩκＢ 키나제 조절용 인돌 또는 벤즈이미다졸 유도체
TW201625620A (zh) 作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法
US7205299B2 (en) Indole derivatives having an apoptosis-inducing effect
CA2999379A1 (fr) Composes 2-oxo-1,2-dihydropyridine-3,5-dicarboxamide utilises en tant qu'inhibiteurs de bromodomaines
WO2022088551A1 (fr) Dérivé d'indazole, son procédé de préparation et son utilisation
CA2871453A1 (fr) Derive de quinazolinedione
CA2526663C (fr) Derives indoliques possedant une activite d'induction de l'apoptose
KR20100132553A (ko) 신규한 ｎ-(2-아미노-페닐)-아크릴아미드
US20190100495A1 (en) Substituted tetrahydroisoquinoline ethylbenzamide anti-cancer agents
CN116870016B (zh) 杂芳环化合物及其医药用途
JP7190755B2 (ja) オキサジノキナゾリンおよびオキサジノキノリン系化合物、ならびに調製方法およびその使用
CN111875583B (zh) 三氮唑衍生物及其制备方法和用途
ZA200509475B (en) Indole derivatives with apoptosis-inducing effect
KR20150105302A (ko) 헤지 호그 신호 경로의 억제제로서 환상 술폰아미드 함유 유도체
CN112851678B (zh) 2，4，7-三取代嘧啶并吲哚化合物抗肿瘤转移作用
CN113493437B (zh) 含苯并咪唑结构的化合物及其制备方法和用途
CN112778154B (zh) 芳基烷基醚化合物及其衍生物，制备方法、药物组合物和应用
CN115803325B (zh) 一种egfr抑制剂及其制备方法和应用
CN108912035B (zh) 一种具备抗肿瘤活性的吲哚酰胺类化合物
TWI344462B (en) Indole derivatives having an apoptosis-inducing effect
CN116987073A (zh) 一种PI3Kα/HDAC6亚型选择性双重抑制剂及其应用

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140527